CTNM — Contineum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855175 ·
Last close
$13.18
Market Cap
$434.39M
52W High
$17.78
52W Low
$8.60
ADV30
634,893
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -17,428,000 | -15,154,000 | 250,367,000 | 14,711,000 | 10,707,000 |
| Mar 2026 | 0 | — | -16,904,000 | -14,456,000 | 261,349,000 | 20,158,000 | 11,308,000 |
| Dec 2025 | 0 | — | -17,115,000 | -15,156,000 | 276,642,000 | 75,603,000 | 15,653,000 |
| Sep 2025 | 0 | — | -14,932,000 | -12,792,000 | 190,847,000 | 42,633,000 | 10,377,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,006,000
Investing CF
$-66,966,000
Financing CF
$113,899,000
CapEx
$-458,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-206,990,000
Inventory
—
Receivables
—
ST Investments
$221,840,000
EBIT TTM
$-66,379,000
Pretax Income TTM
$-57,558,000
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -68,059,000 | -59,978,000 | 276,642,000 | 15,653,000 | 260,989,000 | -55,312,000 |
| Dec 2024 | 0 | -50,894,000 | -42,258,000 | 212,847,000 | 14,781,000 | 198,066,000 | -32,845,000 |
| Dec 2023 | 50,000,000 | 16,077,000 | 22,720,000 | 130,386,000 | 198,322,000 | -67,936,000 | 19,349,000 |
| Dec 2022 | 0 | -22,720,000 | -24,253,000 | 50,636,000 | 143,848,000 | -93,212,000 | -20,121,000 |
TTM Snapshot
Revenues TTM
$8,501,000
NetIncome TTM
$-58,444,000
OpCashFlow TTM
—
Assets (Latest)
$261,349,000
Forward EPS
$-1.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc. | $431.94M | $8.01 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $429.91M | $0.41 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $442.01M | $8.61 | — |
| IBO | IMPACT BIOMEDICAL INC. | $443.15M | $4.11 | — |
| KMDA | KAMADA LTD | $448.70M | $7.78 | — |
News headlines (Yahoo Finance, 1h cache)
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
2026-09-24 23:04 · Yahoo
Sector Update: Healthcare Stocks Ease Late Afternoon
2026-09-15 19:52 · Yahoo
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
2026-09-14 21:32 · Yahoo
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
2026-08-25 20:05 · Yahoo
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
2026-07-30 20:05 · Yahoo
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
2026-07-09 16:00 · Yahoo
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
2026-06-01 20:05 · Yahoo
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
2026-05-25 13:55 · Yahoo
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
2026-05-22 12:03 · Yahoo
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
2026-09-30 16:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.